HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Caribou Biosciences (NASDAQ:CRBU) and maintained a $9 price target.
July 17, 2024 | 10:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Caribou Biosciences (NASDAQ:CRBU) and maintained a $9 price target.
The reiteration of a Buy rating and the maintenance of a $9 price target by a reputable analyst can boost investor confidence in Caribou Biosciences, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100